SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)
Titel:
SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)
Auteur:
Retz, Margitta Bedke, Jens Bögemann, Martin Grimm, Marc-Oliver Zimmermann, Uwe Müller, Lothar Leiber, Christian Teber, Dogu Wirth, Manfred Bolenz, Christian van Alphen, Robbert De Santis, Maria Beeker, Aart Lehmann, Jan Indorf, Martin Frank, Melanie Bokemeyer, Carsten Gschwend, Jürgen E.